WEB Aneurysm Embolization Devices feature CE mark.
Press Release Summary:
SL (Single Layer) series of WEB® Aneurysm Embolization Devices are made possible via MicroBraid™ technology, which is dense mesh constructed from extremely fine Nitinol wires. Low profile and enhanced navigability allows physicians to treat range of aneurysms. While WEB SL and WEB SLS have distinct shapes designed to accommodate varying aneurysm morphologies, both configurations are available in sizes from 4–11 mm and are designed for delivery through VIA microcatheters.
Original Press Release:
Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices
ALISO VIEJO, Calif. -- Sequent Medical, Inc. announced today that it has received CE mark for the SL ("Single Layer") family of WEB(®) Aneurysm Embolization Devices, and has commenced a controlled release of these new models in select neurovascular centers in Europe. The SL family offers a lower profile and superior navigability that will enable physicians to treat a broader range of aneurysms with the WEB platform.
The SL configurations are made possible by further advancement of Sequent Medical's proprietary MicroBraid(TM) technology, a dense mesh constructed from a large number of extremely fine Nitinol wires. Unlike conventional medical braids, MicroBraid features a mix of wire diameters and high wire counts to achieve a tailored balance of compliance, porosity and profile across device sizes.Â
The SL family consists of two separate product configurations, the WEB SL and WEB SLS, each with a distinct shape designed to accommodate varying aneurysm morphologies. Both configurations are available in multiple sizes ranging from 4-11 mm and are designed for delivery through Sequent Medical's VIA microcatheters.
The WEB SL and WEB SLS will build upon the growing experience with the original dual layer WEB, now referred to as the WEB DL configuration, which has now been used to treat over 280 ruptured and unruptured aneurysms in Europe and Latin America.
"Sequent Medical has responded to physicians' requests in developing the WEB SL configurations," said Prof Laurent Pierot, MD PhD, Head of the Department of Radiology, Maison Blanche Hospital, Reims, France. "The SL family promises to expand the range of aneurysms physicians can treat with the WEB while continuing to offer the familiar straightforward procedure we've come to value with the WEB DL."
"Combined with our recently introduced VIA microcatheter line, the introduction of the SL products demonstrates Sequent Medical's ongoing commitment to developing a broad portfolio of innovative catheter-based technologies for neurovascular specialists and their patients," said Tom Wilder, President and Chief Executive Officer.
About Sequent Medical, Inc.
Founded in 2007, Sequent Medical, Inc. (www.sequentmedical.com) is a privately held venture backed medical-device company that is dedicated to the development of innovative catheter-based neurovascular technologies. The WEB Aneurysm Embolization System and VIA Microcatheter have both received the CE mark. They are not approved for or available for sale or use in the United States. Sequent Medical, Inc. is headquartered in Aliso Viejo, California, and has European operations based in Bonn, Germany.
About The WEB Aneurysm Embolization System
Building upon the foundation of endovascular embolic coils, the WEB is a low porosity intrasaccular neurovascular embolization device that is designed to bridge the neck of a ruptured or unruptured intracranial aneurysm and to promote rapid, peri-procedural stasis. The WEB enables physicians to treat a broad range of intracranial aneurysms with the familiarity of an intrasaccular approach while using established biomaterials. The WEB product portfolio consists of the original WEB DL configuration and the recently introduced WEB SL and WEB SLS offerings.
CONTACT: Thomas Wilder, President & CEO, +1-949-830-9600, fax, +1-949-830-9658
